Guided Therapeutics (GTHP) Net Margin (2010 - 2025)

Guided Therapeutics has disclosed Net Margin across 16 years of filings, most recently posting 210.51% for Q4 2025.

• In Q4 2025, Net Margin rose 6978949.0% year-over-year to 210.51%; the TTM figure through Jun 2026 stood at 560.62% (up 173684.0% YoY), while the FY2025 annual figure was 436.25%, up 3657804.0% from the prior year.
• Net Margin came in at 210.51% for Q4 2025 at Guided Therapeutics, up from 1308.33% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 210.51% in Q4 2025 to a low of 70000.0% in Q4 2024.
• Average Net Margin over 5 years is 16039.73%, with a median of 4025.0% recorded in 2023.
• Year-over-year, Net Margin tumbled 6853438 bps in 2024 and soared 6978949 bps in 2025.
• Over 5 years, Net Margin stood at 848.33% in 2021, then slumped by 4041 bps to 35133.33% in 2022, then surged by 96 bps to 1465.62% in 2023, then tumbled by 4676 bps to 70000.0% in 2024, then surged by 100 bps to 210.51% in 2025.
• Per Business Quant data, the three most recent Net Margin figures were 210.51% in Q4 2025, 1308.33% in Q3 2025, and 731.62% in Q2 2025.